Estimation of hepatic repercussion in obesity and cardiometabolic risk

• Mª Teófila Vicente-Herrero ^{[1] [6]} ; Mª Victoria Ramírez-Iñiguez de la Torre ^{[1] [2]} ; Luisa Capdevila García ^{[1] [3]} ; Ana Victoria Bueno Atkinson ^[4] ; Ángel Arturo López González ^{[5] [6] [7]}
  1. [1] Obesity and work group-Asociación Española de especialistas en Medicina del Trabajo-AEEMT.
  2. [2] Occupational Health and safety Services of Correos, Albacete (Spain).
  3. [3] Occupational Health and safety Services MAPFRE, Valencia (Spain).
  4. [4] Occupational Health Nurse. MAPFRE-UBS Majadahonda. Madrid (Spain).
  5. [5] Occupational Health and safety Services Servei de Salut de les Illes Balears.
  6. [6] ADEMA-HEALTH Group of the University Institute of Health Sciences-IUNICS Illes Balears (Spain).
  7. [7] University School ADEMA, Palma de Mallorca (Spain).

  Mostrar afiliaciones +
• Localización: Academic Journal of Health Sciences: Medicina Balear, ISSN-e 2255-0560, Vol. 37, Nº. 5, 2022, págs. 93-98
• Idioma: inglés
• DOI: 10.3306/AJHS.2022.37.05.93
• Títulos paralelos:
  • Estimación de repercusión hepática en obesidad y riesgo cardiometabólico
• Enlaces
  • Texto completo (pdf)
• Dialnet Métricas: 1 Cita
• Resumen
  • español

    Introducción: La obesidad es una pandemia mundial con repercusión cardiometabólica y riesgo aumentado en el desarrollo de enfermedad hepática no alcohólica. Es objetivo de este trabajo relacionar el riesgo cardiometabólico en obesidad con el riego de repercusión hepática en población trabajadora.

    Método: Estudio descriptivo transversal en 815 trabajadores entre marzo de 2020- junio de 2021. Se utilizan las calculadoras FLI- fatty liver index y FIB-4 Index for liver fibrosis y su relación con el índice de masa corporal y el riesgo cardiometabólico.

    Resultados: Se encontró una mayor presencia de valores altos de FLI y FIB-4 en los grupos con mayor nivel de riesgo cardiometabólico y con IMC en niveles de sobrepeso/obesidad, con resultados más desfavorables en hombres.

    Conclusiones: En trabajadores con obesidad y riesgo cardiovascular o síndrome metabólico se detecta mayor riesgo de repercusión hepática cuantificada con FLI y FIB-4.

  • English

    Introduction: Obesity is a global pandemic with cardiometabolic repercussions and increased risk in the development of non-alcoholic liver disease. The objective of this work is to relate the cardiometabolic risk in obesity with the risk of hepatic repercussion in the working population.

    Method: Cross-sectional descriptive study in 815 workers between March 2020-June 2021. The FLI-fatty liver index and FIB-4 Index for liver fibrosis calculators and their relationship with body mass index and cardiometabolic risk are used.

    Results: A greater presence of high FLI and FIB-4 values was found in groups with a higher level of cardiometabolic risk and with BMI at levels of overweight/obesity, with more unfavorable results in men.

    Conclusions: In workers with obesity and cardiovascular risk or metabolic syndrome, a higher risk of hepatic repercussion quantified with FLI and FIB-4 is detected.

• Referencias bibliográficas
  • Arroyo-Johnson C, Mincey KD. Obesity Epidemiology Worldwide. Gastroenterol Clin North Am. 2016 Dec;45(4):571-579. doi: 10.1016/j.gtc.2016.07.012.
  • Healthy people 2030. https://health.gov/healthypeople/objectives-and-data/browse-objectives/overweight-and-obesity (accessed 2022, March...
  • Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019 Mar;92:6-10. doi: 10.1016/j.metabol.2018.09.005. Epub...
  • Apovian CM. Obesity: definition, comorbidities, causes, and burden. Am J Manag Care. 2016 Jun;22(7 Suppl):s176-85
  • Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019 Mar;92:98-107....
  • Ortega FB, Lavie CJ, Blair SN. Obesity and Cardiovascular Disease. Circ Res. 2016 May 27;118(11):1752-70. doi: 10.1161/CIRCRESAHA.115.306883.
  • Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest. 2017 Jan 3;127(1):1-4. doi: 10.1172/JCI92035....
  • Lemieux I, Després JP. Metabolic Syndrome: Past, Present and Future. Nutrients. 2020 Nov 14;12(11):3501. doi: 10.3390/nu12113501.
  • Azzu V, Vacca M, Virtue S, Allison M, Vidal-Puig A. Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism:...
  • Milić S, Lulić D, Štimac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations....
  • World Health Organization 2020. Body mass index – BMI. Available at: https://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi....
  • Vicente-Herrero MT, Ramírez-Iñiguez de la Torre MV, López González AA. Estimación del nivel de riesgo cardiometabólico en trabajadores...
  • Buitrago Ramírez F, Cañón Barroso L, Díaz Herrera N, Cruces Muro E, Bravo Simón B, Pérez Sánchez I. Comparación entre la tabla del...
  • Registre Gironí del Cor. Validación de las tablas Framigrahm-Regicor [Validation of Framigrahm-Regicor tables] ;2022 https://regicor.cat/es/presentacion/tablas-de-framingham-regicor/
  • Grau M, Marrugat J. Risk Functions and the Primary Prevention of Cardiovascular Disease. Rev Esp Cardiol. 2008;61(4):404-16.
  • Taberner R. Calculadora multiplataforma para síndrome metabólico y riesgo cardiovascular en pacientes con psoriasis [Multiplatform...
  • Tutunchi H, Ebrahimi Mameghani M, Ostadrahimi A, Asghari Jafarabadi M. What are the optimal cut-off points of anthropometric...
  • Bello Chavolla OY, Antonio Vila NE, Vargas Vázquez A, Viveros Ruiz TL, Almeda Valdes P, Gómez Velasco D, et al. Metabolic Score...
  • Vicente-Herrero MT, Ramírez-Iñiguez de la Torre MV, Capdevila García L, Partida-Hanon A, Reinoso-Barbero L, López González...
  • Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate...
  • Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based...
  • Ros E. The PREDIMED study. Endocrinol Diabetes Nutr 2017;64(2):63-6.
  • Ferreira-Pêgo C, Nissensohn M, Kavouras SA, Babio N, Serra-Majem L, Martín Águila A, et al. Beverage Intake Assessment...
  • Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country...
  • Román Viñas B, Ribas Barba L, Ngo J, Serra Majem L. Validación en población catalana del cuestionario internacional de actividad física [Validity...
  • Marques A, Peralta M, Naia A, Loureiro N, de Matos MG. Prevalence of adult overweight and obesity in 20 European countries, 2014....
  • Engin A. The Definition and Prevalence of Obesity and Metabolic Syndrome. Adv Exp Med Biol. 2017;960:1-17. doi: 10.1007/978-3-319-48382-5_1.
  • Piché ME, Poirier P, Lemieux I, Després JP. Overview of Epidemiology and Contribution of Obesity and Body Fat Distribution...
  • Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological...
  • Golabi P, Sayiner M, Fazel Y, Koenig A, Henry L, Younossi ZM. Current complications and challenges in nonalcoholic steatohepatitis screening...
  • Castera L. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. Semin Liver Dis. 2015 Aug;35(3):291-303. doi: 10.1055/s-0035-1562948....